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Abstract: There is robust epidemiological evidence for the beneficial effects of broccoli consumption
on health, many of them clearly mediated by the isothiocyanate sulforaphane. Present in the
plant as its precursor, glucoraphanin, sulforaphane is formed through the actions of myrosinase,
aβ-thioglucosidase present in either the plant tissue or the mammalian microbiome. Since first isolated
from broccoli and demonstrated to have cancer chemoprotective properties in rats in the early 1990s,
over 3000 publications have described its efficacy in rodent disease models, underlying mechanisms
of action or, to date, over 50 clinical trials examining pharmacokinetics, pharmacodynamics and
disease mitigation. This review evaluates the current state of knowledge regarding the relationships
between formulation (e.g., plants, sprouts, beverages, supplements), bioavailability and efficacy,
and the doses of glucoraphanin and/or sulforaphane that have been used in pre-clinical and clinical
studies. We pay special attention to the challenges for better integration of animal model and clinical
studies, particularly with regard to selection of dose and route of administration. More effort is
required to elucidate underlying mechanisms of action and to develop and validate biomarkers
of pharmacodynamic action in humans. A sobering lesson is that changes in approach will be
required to implement a public health paradigm for dispensing benefit across all spectrums of the
global population.
Keywords: broccoli; sulforaphane; glucoraphanin; myrosinase; chemoprotection; allometric scaling;
clinical trials; Nrf2; toxicity
1. Introduction
1.1. Epidemiology of Broccoli and Health
The collective retrospective (observational), prospective, and interventional evidence for the
beneficial effects of broccoli on health is robust. The former two categories will be briefly summarized
herein, and the latter make up the bulk of this review. Broccoli was thought to have been domesticated
in the 1500s, brought to the UK in the early 1700s, and to the future United States in the late 1700s, but
was little-known in the USA until the 1920s [1]. Thus, as a relatively new crop, one can only point to
about a century of relatively widespread consumption. The epidemiology of broccoli′s impact on health
covers precisely half of that century, beginning with Graham′s early work showing a dose-response
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relationship between the consumption of broccoli and other cruciferous vegetables, on colon cancer [2].
Since then there have been impressive demonstrations of risk reduction associated with cruciferous
vegetables and/or broccoli for bladder cancer [3] and prostate cancer [4] just to name a few. We and
others have recently reviewed the growing body of epidemiologic and mechanistic work implicating
cruciferous vegetables in general, broccoli specifically, and sulforaphane, with respect to its association
with neurologic, neoplastic, dermatologic, and other conditions (e.g., [5–9]). Organizations including
the World Cancer Research Fund and the American Institute for Cancer Research have chosen to
highlight lifestyles (a Mediterranean type diet) and food groups (non-starchy vegetables or fruit) as
featuring strongly in cancer prevention, and they have moved away from recommending specific fruits
or vegetables vis à vis cancer risk [10]. However, all evidence points to broccoli and more specifically
to sulforaphane from broccoli, and its biogenic precursor glucoraphanin, as being protective against a
variety of chronic, and even infectious (e.g., Helicobacter pylori) conditions [11].
1.2. Discovery of Sulforaphane as a Bioactive Isothiocyanate
Sulforaphane was described in the middle of the last century, as an antibiotic, and was isolated
from red cabbage, and from the western USA rangeland weed hoary cress [12]. Various groups
have since synthesized it, but Talalay and Zhang were the first to isolate it from broccoli [13] and to
demonstrate its cancer protective properties [14]. Its biogenic precursor, glucoraphanin, was then
found in abundance in broccoli sprouts and sulforaphane was confirmed to be active in animal
carcinogenesis models [15]. Structure-activity evaluation of a series of over 100 synthetic analogs made
by Posner and colleagues did not find a more potent inducer of cytoprotective (Phase 2) enzymes
than sulforaphane [16], and indeedeme sulforaphane remains one of, if not, the most potent naturally
occurring inducers yet discovered [17]. We and many others have identified subsequently multiple
pathways and metabolic consequences of this molecule’s presence in mammalian cells, tissues, and
in the human body [8,18,19]. While far too numerous to review herein, we note this multiplicity of
effects has been well reviewed by others [20–22]. Our early work showed that in the undamaged plant
there is very little if any free sulforaphane, all of it being present in the form of its biologically inactive
precursor glucoraphanin [15]. Thus, it is important to consider the factors controlling glucoraphanin
biosynthesis in plants.
1.3. Biosynthesis and Function of Glucoraphanin in Broccoli
The glucosinolate glucoraphanin is derived from the amino acid methionine. The biosynthetic
pathway leading to glucoraphanin formation in natura is elaborate and includes three separate stages
(Scheme 1) [23,24]. The first stage results in the elongation of the methionine side chain by two
methylene groups. The second stage forms the core glucosinolate structure. The third stage constitutes
a secondary modification of the glucosinolate side chain.
During the first stage (Scheme 1a), a cytoplasmic branched chain amino acid aminotransferase
(BCAT) catalyzes the transamination of methionine to give 2-oxo-4-methylthiobutanoic acid. In turn,
this α-keto acid is elongated by two methylene groups in a cyclical mechanism which involves two
rounds of three successive transformations that take place in the chloroplast: (i) a condensation with
acetyl-CoA, which is catalyzed by a methylthioalkyl malate synthase (MAM); (ii) an isomerization
catalyzed by aconitase (AC); (iii) an oxidative decarboxylation catalyzed by an isopropylmalate
dehydrogenase (IPMDH). The final product of these transformations, 2-oxo-6-methylthiohexanoic acid,
is converted to dihomomethionine in a transamination reaction catalyzed by a BCAT.
During the second stage (Scheme 1b), dihomomethionine undergoes a cytochrome P450
(CYP)-mediated conversion to an aldoxime, which is then further oxidized to a nitrile oxide and
subsequently conjugated to a sulfur donor, such as glutathione (GSH). The conjugation reaction
can occur non-enzymatically or can be catalyzed by a glutathione S-transferase. The resulting
S-alkyl-thiohydroxymate is converted to a thiohydroxymate in a reaction catalyzed by the C-S lyase SUR1.
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Figure 1. Biosynthesis of glucoraphanin, its hydrolysis to form the isothiocyanate sulforaphane, and 
metabolism of sulforaphane. The highly reactive isothiocyanate sulforaphane is produced in plants 
as an inert precursor, the glucosinolate glucoraphanin. Its biosynthetic pathway originates from the 
amino acid methionine and proceeds in three stages: (i) methionine side chain elongation by two 
methylene groups (a); (ii) formation of the core glucosinolate structure (b); (iii) secondary 
modification of the glucosinolate side chain (c); Upon disruption of the plant tissue integrity, 
glucoraphanin comes into contact with myrosinase, which catalyzes the hydrolysis of glucoraphanin 
to give sulforaphane (d); In mammalian cells, sulforaphane is metabolized through the mercapturic 
acid pathway, and can also undergo an interconversion to erucin (e). 
Scheme 1. Biosynthesis of glucoraphanin, its hydrolysis to form the isothiocyanate sulforaphane, and
metabolism of sulforaphane. The highly reactive isothiocyanate sulforaphane is produced in plants as
an inert precursor, the glucosinolate glucoraphanin. Its biosynthetic pathway originates from the amino
acid methionine and proceeds in three stages: (i) methionine side chain elongation by two methylene
groups (a); (ii) formation of the core glucosinolate structure (b); (iii) secondary modification of the
glucosinolate side chain (c); Upon disruption of the plant tissue integrity, glucoraphanin comes into
contact with myrosinase, which catalyzes the hydrolysis of glucoraphanin to give sulforaphane (d);
In mammalian cells, sulforaphane is metabolized through the mercapturic acid pathway, and can also
undergo an interconversion to erucin (e).
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Because this enzyme requires a free amino group within the substrate, an intermediate step is
required: The hydrolytic removal of the γ-glutamyl residue within the conjugate between glutathione
and the activated aldoxime, a reaction catalyzed by γ-glutamyl peptidase (GGP). The last steps of
the second stage are a glucosyltransferase-mediated S-glucosylation resulting is the formation of a
desulfoglucosinolate, followed by sulfation catalyzed by a sulfotransferase (ST). Thus, the parent
glucosinolate, 4-methylthiobutyl glucosinolate (glucoerucin) is produced.
During the final stage (Scheme 1c), a secondary modification of the glucosinolate side chain occurs.
This is accomplished by an S-oxygenation reaction, which is catalyzed by a flavin monooxygenase
(FMO). Together, these elaborate biotransformations, which involve 13 enzymes, result in the synthesis
of glucoraphanin. Notably, in Arabidopsis the biosynthesis of glucosinolates is regulated by light (being
downregulated in prolonged periods of darkness and greatly increased following exposure to light)
and shows diurnal variations that are coordinated with those of general sulfur metabolism [25].
Glucoraphanin is chemically stable and biologically inert. However, following plant tissue
injury, such as biting or chewing, glucoraphanin comes in contact with the enzyme myrosinase,
a ß-thioglucosidase, which in the intact plant is physically separated from its substrate. Myrosinase
catalyzes the hydrolysis of glucoraphanin to liberate glucose and form an unstable aglucone (Scheme 1d)
that spontaneously rearranges to give rise to a range of products, the most reactive of which is the
isothiocyanate sulforaphane. Importantly, mammalian cells do not produce myrosinases; however,
the conversion of glucoraphanin to sulforaphane still occurs in mammals. It is carried out by the
bacterial microflora of the gastrointestinal tract and can be greatly reduced by antibiotic treatment or
mechanical bowel cleansing [26]. Of note, this microbially-mediated conversion of glucoraphanin has
been exploited in a recent study to generate high concentrations of sulforaphane locally in the colon of
mice [27].
In plants, the main function of the glucosinolates is considered to be defense against pathogens and
herbivores, and this has largely been attributed to the isothiocyanate hydrolytic products. Resistance
to pathogens positively correlates with the glucosinolate content of the plant [28], which also affects
the fungal species composition in the soil [29]. In addition, there is a correlation between alterations
in the glucosinolate profile of the plant and basic physiological processes, such as photosynthesis
and growth, that occur during abiotic stress, including drought, extreme temperatures, light, salinity,
and nutrient deprivation [30]. Taken together, these correlations suggest that the glucosinolates
function for protection of the plant against a wide array of environmental challenges. It is therefore not
surprising that domesticated lines of Brassica oleracea have lower glucosinolate levels compared to
wild species [31]; conversely, the glucoraphanin content of certain wild Brassica species (B. villosa)
is high, and this species has been used to generate broccoli hybrids with enhanced concentrations
of glucoraphanin [32]. In addition to their role in plant defense, high levels of isothiocyanates have
been shown to reduce the biomass of the plant, and interestingly, mutants deficient in glutathione
biosynthesis are more susceptible than their wild-type counterparts to the growth-inhibitory effect
sulforaphane [33], suggesting similarities in sulforaphane metabolism in plants and mammals.
1.4. Glucoraphanin Levels in Broccoli
Glucoraphanin occurs in all tissues of broccoli plants, though it is most abundant in the aerial
portions and the developing florets (flower buds) and ultimately the seeds, are richest in this compound
(Figure 1). Although two or three other edible cruciferous (Brassica) species contain significant amounts
of glucoraphanin, it is not as widespread as popular culture would have it. In one sampling of 31 fresh,
uncooked broccoli (Brassica oleracea var. italica) heads, each from different Baltimore area supermarkets,
we found a mean of 0.38 µmol glucoraphanin per gram fresh weight, but with a range of from less than
0.005 to 1.13 µmol/gram [34]. Levels of glucoraphanin when tested in over 75 different genotypes of
field-grown hybrid broccoli averaged 0.88 and 1.10 µmol glucoraphanin per gram fresh weight when
grown in the same fields in two consecutive years [35]. Further work with 32 different genotypes grown
across three different years, in the field and the greenhouse produced a similar range of values and a
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mean glucoraphanin content in broccoli heads of 0.36 µmol per gram fresh weight [36]. Glucoraphanin
level in broccoli seeds was judged to be largely determined by genotype, though the environment in
which the plants are grown (e.g., location, year, drought, pollution, and disease pressure) also plays a
clear and significant role [37].
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Figure 1. On a weight basis, glucoraphanin (right axis) is most abundant in the seeds of the broccoli
plant. Upon enzymatic conversion to sulforaphane, the capacity of extracts of these plants to induce
or up-regulate phase 2 enzymes such as NQO1 in mammalian cells, follows precisely the same curve
(left axis).
2. Broccoli-Based Intervention in Rodents
2.1. Formulation, Route of Administration and Dose
We surveyed the now vast literature on the evaluation of sulforaphane as an agent for disease
prevention in mous and rat models. While some studies reported feeding animals with broccoli
(typically lyophiliz d) incorporat d into rodent diets, the large majority h ve examined effi acy
(monitored through molecular, biochemical, biolog cal or pathologic l endpoints) of sulforaphane as
a discrete, commercially av ila le research-grade chemical. Of note, while R-sulforaphane is found
naturally, the synthetically derived R,S-sulforaphane has bee likely us d in most animal studies
due to historical matters of availability and relativ co t. Most publications do not direc ly acco nt
for the form of sulf r phane used. Th re s some suggestion that R-sulforaphane shows increased
effectiveness compar d to its racemic R,S counterpar i various models. This review focuse on
animal studies using sulf raph n as the test article s few of the dietary tudie with broccoli-based
prep ra ions attempted to ccurately d termine the administer d bioactive ose.
An mal s udies have principally used three routes of administration for sulforaphane: Oral,
intraperitoneal and topical. Figure 2 highlights the distributions of doses selected by investigators
for oral or intraperitoneal dosing to mice. Oral administration is the route typically used by the
NCI in chemopreventive agent development [39]. Yet, somewhat paradoxically as depicted in
Figure 2, intraperitoneal administration has been the most commonly employed route for studies with
sulforaphane. Presumably this choice reflects relative ease of administration to animals rather than
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attempted mimicry of a route most appropriate for administration of a dietary compound or matrix
to humans.
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Figure 2. Distribution of daily doses of sulforaphane administered to mice as reported in the literature
based on route of administration and efficacy outcome. Top panel, oral (gavage or in diet); bottom panel,
intraperitoneal administration. Where necessary, dose extrapolations assumed 25 g body weight and
dietary intake of 4 g food/mouse/day [38].
That said, dose ranges for intraperitoneal administration appears to provide roughly equivalent
pharmacological efficacy to oral dosing with sulforaphane, presumably reflecting the excellent
bioavailability of this agent. Doses selected for oral administration have spanned a greater than
4-log range and those for intraperitoneal administration an overlapping 3-log range. The median
effective dose of sulforaphane in the published literature by oral administration is 175 µmol/kg body
weight and by intraperitoneal administration is 113 µmol/kg. Likely reflecting publication bias, most
studies irrespective of route of administration report a positive outcome on efficacy. Nonetheless,
also informative, is the observation that studies, albeit far fewer in number, report a lack of efficacy
in some models: E.g., tumor xenografts or chemical carcinogenesis, bacterial infections, airways
inflammation and cerebral ischemia. For most of the listed “not effective” responses, significant
responses were reported for study endpoints at higher doses as part of dose-response evaluations.
Very few studies report harmful outcomes but are notable as discussed later. Topical application of
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sulforaphane has been used effectively in limited settings for mitigation of skin erythema, inflammation
or photocarcinogenesis.
The literature surveyed is listed and annotated for studies employing oral (Table S1), intraperitoneal
(Table S2), and topical (Table S3) administration of sulforaphane to mice as well as oral administration
to rats (Table S4).
2.2. Efficacy Endpoints: Mechanisms Versus Dose, Risks and Benefits
Relatively few studies have rigorously examined the mechanisms of action in vivo of sulforaphane
that underlie the reported biological outcomes (Figure 3). This experimental paucity lies in stark
contrast to the multitude of studies reporting on mechanistic actions identified in cell culture systems
as reviewed elsewhere [40,41]. A recent bibliometric review indicates that sulforaphane is the most
cited natural product activator of Nrf2 signaling [42]. Indeed, several studies have compared the action
of sulforaphane on Nrf2 signaling and disease prevention by comparing outcomes in wild-type and
Nrf2-knockout mice. In several cases, Nrf2-dependent effects have been linked to anti-inflammatory
actions. In both settings (with some overlapping studies), a wide range of doses have been employed,
indicating at least lower bounds for efficacy (3–10 µmol/kg). Studies examining the induction of
apoptosis in vivo, principally in xenograft anti-tumorigenesis experiments have utilized high doses
(>60 µmol/kg). A similar reliance on higher doses is reflected in studies on the inhibition of histone
deacetylase (HDAC) activities (>100 µmol/kg). Absence of data in these cases should be distinguished
from absence of effect at lower doses. Further experiments are required. To this point, relatively few
dose-response studies have been conducted in vivo, so it is not possible to appreciate whether a plot of
the relationship of response(s) to sulforaphane dose may take the form of “S”, “∩” or possibly some
other shape. No maximally effective doses have been established—They are likely to vary depending
upon the endpoint.
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Figure 3. Distribution of oral doses of sulforaphane administered to mice in studies that included
experimental examination of underlying mechanisms in vivo. Data are as reported and interpreted in the
original publications. Listed mechanisms are not necessarily exclusive. Nrf2 KO: Nrf2 knockout. Some
studies included comparisons of responses in wild-type and Nrf2 KO mice to impute Nrf2-dependence
and are also included in the listed mechanisms (primarily “anti-inflammation”).
Several studies conducted with higher doses of sulforaphane in mice do describe toxicities that
require careful attention to risk-benefit analyses and determination of therapeutic or prophylactic
indices. Socala et al. [43] examined the toxicity profile of sulforaphane in mice after intraperitoneal
injection of single doses. High doses of sulforaphane produced marked sedation (at 150–300 mg/kg),
hypothermia (at 150–300 mg/kg), impairment of motor co rdination (at 200–300 mg/kg), decrease
in skeletal muscle str ngth (at 250–300 mg/kg), and deaths (at 200–300 mg/kg). Th LD50 value f
lf in mic was estimated to be 213 mg/kg i.p. (1203 µmol/kg). This v lue is bout 10-fold
higher than the median dose report d for effic cy outcomes in mice. Sulforaphane (at 100 mg/kg)
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potentiated the anticonvulsant efficacy of carbamazepine in a seizure test. This drug interaction
could have been pharmacokinetic in nature, a form of interaction also considered but not observed in
humans [44]. Shorey et al. [45] observed increased morbidity and no reduction in lung tumorigenesis
in offspring born to mothers receiving transplacental and lactational exposure to the carcinogen
dibenzo[def,p]chrysene and supplemented with dietary sulforaphane (400 ppm) or its primary whole
food source, broccoli sprouts (10% wt/wt), contrasting to many reports of chemoprotection in adult
animal models. Of potentially greatest concern is the study of Tao et al. [46]. They utilized a chemical
carcinogenesis model with vinyl carbamate (A/J mice) and a genetic model (LSL-K-rasG12D/+ mice)
to induce lung cancers. Mice were treated intraperitoneally with 12.5 mg/kg (75.5 µmol/kg) (5 doses,
once every three days during tumor induction (pre-treatment) or 12.5 mg/kg every three days, starting
one week after tumor induction for 13 weeks (post-treatment). In the chemical carcinogenesis model,
pre-treatment reduced the number of tumors, and post-treatment slightly promoted tumors. In the
genetic model, pre-treatment with SF had no effect on tumor number, but post-treatment increased
tumor number and size. Given observed efficacy in humans at doses <0.5 µmol/kg of sulforaphane,
and providing allowance for allometric scaling from mice and the improved bioavailability with i.p.
dosing, there is only a 10-fold difference in safety margin. It should be noted that Kombairaju et al. [47]
reported that prolonged sulforaphane treatment (0.5 mg, 5d/wk for 3 mo. by means of a nebulizer)
did not enhance tumorigenesis in the same LSL-K-rasG12D/+ mouse model. In settings of long-term
preventive interventions with sulforaphane or a broccoli-based formulation, careful consideration will
need to be given to matters of dose, schedule and duration.
3. Broccoli-Based Clinical Trials
3.1. Sulforaphane Pharmacokinetics and Pharmacodynamics
Upon entry into the mammalian cell, sulforaphane is conjugated with GSH in a GST-catalyzed
reaction, entering the mercapturic acid pathway (Scheme 1e). The glutathione conjugate of sulforaphane
is subjected to a series of sequential conversions catalyzed byγ-glutamyltranspeptidase (γGT), followed
by cysteinylglycinase (CGase), and N-acetyltransferase (NAT). The final product is the N-acetylcysteine
conjugate of sulforaphane (mercapturic acid). In addition, sulforaphane can undergo an interconversion
to erucin [1-isothiocyanato-4-(methylthio)butane], which is then metabolized in an identical manner to
that for sulforaphane [48,49].
Sulforaphane and its metabolites (dithiocarbamates) can be quantified collectively by cyclocondensation
with 1,2-benzenedithiol, with sensitivity in the picomolar range [50]. This highly sensitive, simple and
convenient method has been widely used to measure the levels of sulforaphane and its metabolites
in blood, plasma, urine and tissues following sulforaphane administration to rodents and humans.
The use of this method revealed that sulforaphane crosses the placental barrier based on detection
of dithiocarbamates in embryos 2 h post-treatment of pregnant mice with a single (5 µmol) dose of
sulforaphane [51]. In addition, methods have been developed to analyze the individual metabolites
following their separation by liquid chromatography coupled with tandem mass spectrometry
(LC-MS/MS) [52,53]. Furthermore, the use of mass spectrometry coupled with stable isotope-labeled
internal standards of sulforaphane [1-isothiocyanato-4-methyl-sulfinyl(1,1,2,2,3,3,4,4-2H8)butane] and
its corresponding mercapturic acid pathway conjugates allows for quantitative, precise, sensitive, and
specific analysis of sulforaphane and its metabolites [54].
With these analytical tools in hand, a number of pharmacokinetic studies have been conducted in
rodents and humans. Thus, following oral administration of an exceedingly high dose of 150 µmol
sulforaphane to 10-week-old female Sprague–Dawley rats, the concentration of dithiocarbamates
in the plasma of the animals increased rapidly reaching a peak (Cmax) of 60 µM 1 h after dosing,
with area under the concentration curve (AUC) of 491 h µmol/L, elimination constant (Kel) of
0.1 h−1, and elimination half-life of 6.7 h [55]. Similarly, following oral administration of 200 µmol
broccoli sprout isothiocyanates to four healthy human volunteers, the peak plasma dithiocarbamate
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concentration (Cmax) was 1.91 ± 0.24 (0.943–2.27) µM 1 h after dosing, with half-life of 1.77 ± 0.13 h,
and clearance of 369 ± 53 mL/min [56]. A study in 20 participants administered 200 µmol sulforaphane
as sulforaphane-rich powder in capsules reported a Cmax of 0.7 ± 0.2 µM at 3 h, with a half-life of
1.9 ± 0.4 h for elimination of sulforaphane equivalents measured by mass spectrometry [57]. Another
pharmacokinetic study, in which a single dose of broccoli soup delivering the equivalent of either
16 µmol or 52 µmol of sulforaphane was administered, reported Cmax of 2.2± 0.8 µM and 7.3± 2.9 µM at
1.5 h and 2 h for the low and the high dose, respectively [53]. A double-blinded, randomized crossover
trial with broccoli soups (prepared from plants with increased glucoraphanin content) delivering
a single dose of 84, 280, or 452 µmol of glucoraphanin documented peak plasma concentrations
(Cmax) of 0.17 ± 0.12, 0.37 ± 0.26, and 0.61 ± 0.40 µM, respectively [52]. Another study reported
plasma dithiocarbamate levels of 0.92 ± 0.72 µM and mean epithelial-/stromal-enriched breast tissue
dithiocarbamate concentration of 1.45 ± 1.12 and 2.00 ± 1.95 pmol/mg tissue for the right and the left
breast, respectively in eight healthy women undergoing reduction mammoplasty who had received a
single dose of a broccoli sprout preparation delivering 200 µmol sulforaphane 1 h prior to surgery [55].
In a double-blind randomized placebo-controlled trial in men presenting for prostate biopsy,
plasma levels of 0.12 µM of sulforaphane and its metabolites were detected after an intervention period
of 4–8 weeks with two daily doses of 100µmol sulforaphane administered 12 h apart [58]. Isothiocyanate
levels of 2.2µM and 500 nM were detected in the plasma and synovial fluid, respectively of patients
with osteoarthritis undergoing knee replacement surgery following consumption of glucosinolate-rich
diets for 2 weeks [59].
A study in healthy subjects who received single oral doses of broccoli sprout extracts containing the
equivalent of 111µmol of glucosinolates or isothiocyanates showed cumulative urinary dithiocarbamate
excretion of 88.9± 5.5 µmol and 13.1± 1.9 µmol for the isothiocyanate and the glucosinolate preparation,
respectively [60]. This study further revealed that for the isothiocyanate preparation, excretion was
consistent and linear over a 25–200µmol dose range, whereas for the glucosinolate preparation, excretion
was highly variable among individuals. These observations are in close agreement with results from a
randomized, placebo-controlled, double-blind Phase I clinical trial, in which isothiocyanate (25 µmol)-
or glucosinolate (25 µmol or 100 µmol)-rich preparations were orally administered to three cohorts
of three healthy human subjects at 8-h intervals for 7 days; one other subject in each cohort received
placebo [61]. Notably, this study showed no evidence of clinically significant adverse events based on
32 types of hematology and chemistry tests, including liver (transaminases) and thyroid (TSH, T3, and
T4) function tests. In agreement, a recent analysis of biochemical parameters of thyroid function in
serum collected from 45 female volunteers that had participated in a randomized clinical trial revealed
no alterations compared to baseline following an intervention for 12 weeks with a broccoli sprout
beverage containing a combination of 40 µmol sulforaphane and 600 µmol of glucoraphanin [62].
The finding that compared to isothiocyanates, oral administration of glucosinolates results in
lower bioavailability, slower elimination, and greater inter-individual variation in excretion was further
strengthened by a larger (50 participants) crossover clinical trial that involved 5-day baseline period
followed by daily administration of broccoli sprout beverages delivering either glucosinolates or their
corresponding isothiocyanates for 7 days, 5-day washout period, and 7-day administration of the
opposite intervention [63]. Using fecal sample collections from five subjects with high 24-h urinary
excretion profiles (‘high converters’) and five subjects with low excretion profiles (‘low converters’),
it was found that ex vivo, the degradation of glucoraphanin was greater in cultures of fecal bacteria
derived from the ‘high converters’ in comparison to the ‘low converters’ [64]. These observations are
consistent with earlier work showing that mechanical cleansing or antibiotic treatment greatly reduce
the glucosinolate conversion in healthy human subjects [26] and indicate that the gastrointestinal
microflora represents a critical factor in determining the extent of gl ucosinolate hydrolysis. In addition
to the inter-individual variations, there are also diurnal variations in the conversion of glucosinolates
to dithiocarbamates, whereby conversion is greater during the day [65]. By contrast, the conversion of
isothiocyanates to dithiocarbamates is higher during the night.
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Overall, in humans, sulforaphane is rapidly absorbed and eliminated with small inter-individual
variations and typical urinary excretion of 70% to 90% of the dose. By contrast, the conversion of
glucoraphanin is slow and with high inter-individual variations. The urinary excretion of sulforaphane
metabolites following intervention with glucoraphanin-containing preparations typically range from
2% to 15% of the dose, being 1% to 45% at the extremes. The differences in inter-individual variations
between sulforaphane and glucoraphanin make, at first glance, the use of sulforaphane much
more attractive for the purposes of dose precision. However, in contrast to its stable glucosinolate
precursor, sulforaphane is unstable, which has prompted the development of stabilized preparations,
such as an α-cyclodextrin-encapsulated form of sulforaphane [66] and a stabilized version of pure
plant-derived sulforaphane, known as Prostaphane® (Nutrinov, Noyal sur Vilaine Cedex, France).
Alternatively, glucoraphanin-rich preparations containing active myrosinase have also been used [67,68].
As formulations differ in their bioavailability (which provides a possible explanation for the differences
in pharmacokinetic parameters reported in the various human studies), the excreted amount of
sulforaphane metabolites in the urine, and not the amount in the administered preparation, provides a
more reliable measure of the actual dose [69].
Similar to the studies of the pharmacokinetics of sulforaphane, nearly all human studies addressing
the pharmacodynamics of sulforaphane have used glucoraphanin- or sulforaphane-rich broccoli-based
preparations. Although there is currently no direct evidence for specific target engagement by
sulforaphane in humans, there is clear evidence for its pharmacodynamic action. Thus, increased
levels of the Nrf2-target enzymes A-class GSTs and NQO1 have been reported in plasma [70] and
saliva [71] of human subjects consuming cruciferous vegetables. In agreement, administration of
glucoraphanin/sulforaphane-rich preparations to healthy volunteers resulted in increased mRNA
or protein levels of NQO1 and GSTs in PBMC, skin punch biopsies, as well as in nasal and buccal
scrapings [72–76].
Broccoli-based glucoraphanin/sulforaphane-rich preparations have been shown to accelerate
the detoxication and excretion of potentially carcinogenetic food contaminants and air pollutants,
offering a very attractive strategy for population-wide reduction in cancer risk due to unavoidable
exposures to pollution. A cross-over clinical trial with 50 human volunteers, which was conducted
in Qidong, China, found statistically significant increases of 20–50% in the urinary excretion levels
of glutathione-derived conjugates of the air pollutants acrolein and benzene following consumption
of sulforaphane- and/or glucoraphanin-rich broccoli sprout-derived beverages [77]. A subsequent
12-week placebo-controlled, randomized clinical trial involving 291 participants from the same area
using broccoli sprout beverages containing a combination of 40 µmol sulforaphane and 600 µmol
glucoraphanin confirmed and extended these findings by showing that the excretion levels of the
glutathione-derived conjugates of benzene and acrolein were significantly increased, by 61% and 23%,
respectively in the volunteers who received the broccoli sprout beverage compared with placebo [78].
Very recently, a randomized, placebo-controlled, multidose intervention trial of a broccoli sprout
beverage, which was conducted in the same area of China, showed a dose-dependent excretion of the
urinary metabolites of sulforaphane, and further found that a treatment regime with daily doses of
40 µmol sulforaphane and 600 µmol glucoraphanin for 10 days, resulting in an urinary excretion of
∼25 µmol sulforaphane metabolites per day, promotes the detoxication of benzene [69].
Global gene expression profiling to evaluate the transcriptional changes in the prostate of men
at high risk for prostate cancer has revealed that consumption of broccoli-rich diets for 6- or 12
months associates with transcriptional changes in signaling pathways involved in inflammation
and carcinogenesis in the prostate tissue [79,80]; importantly, these changes are dose-dependently
attenuated in subjects receiving the glucoraphanin-rich diet [80]. Other pharmacodynamic effects of
interventions with glucoraphanin/sulforaphane in humans include: Increase in the levels of reduced
glutathione in brain [81], enhanced integration of fatty acid β-oxidation with TCA cycle activity [82],
protection against skin erythema caused by exposure to ultraviolet radiation [83,84], reduction in
plasma LDL-cholesterol [85], decrease in the levels of fasting blood glucose and glycated hemoglobin
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in obese patients with dysregulated type 2 diabetes [86], and improvements in social interaction,
behavior, and verbal communication in young men with autism spectrum disorder [87]. Overall,
although the precise molecular mediators are not always known, it is clear that interventions with
glucoraphanin/sulforaphane-rich broccoli preparations in humans lead to diverse beneficial effects.
3.2. Clinical Studies with Broccoli-Based Preparations: Efficacy
Broccoli-based preparations consist almost exclusively of either glucoraphanin, sulforaphane,
glucoraphanin with added active myrosinase, the raw, cooked, or dried vegetables themselves
(either broccoli or broccoli sprouts), or extracts of broccoli seeds or sprouts—glucoraphanin-rich,
sulforaphane-rich, or both. These studies are, of course, not all straightforward, and measurement of
the broccoli-derived ingredients can be a source of mystery, obfuscation, and confusion, that is readily
exploited by the supplement industry. Nonetheless, many clinical studies have now been done, and
some overarching learnings can begin to be formulated. We and others have spent much time assessing
bioavailability, conversion of glucoraphanin to sulforaphane, safety, and the classic ADME (absorption,
distribution, metabolism, and excretion) pharmacokinetic parameters discussed in a previous section
of this review. Efficacy has been studied much less thoroughly, but a picture is beginning to emerge.
The following areas (in alphabetical order) have received special attention:
3.2.1. Aflatoxin Toxicity
The levels of aflatoxins from stored, subsistence seeds (corn and peanuts) in the Qidong area of
coastal China near Shanghai, have in recent history been exceedingly high, as has associated incidence
of liver cancer. Broccoli sprouts have been successfully piloted as a preventive intervention, and much
data has been generated on safety and efficacy [biomarkers], as well as tolerance and acceptance by the
local population [88,89];
3.2.2. Air Pollution Detoxification
The natural laboratory in Qidong further served to study the effects of broccoli spouts on
detoxication of volatile organic air pollutants [69,77,78,90]. Others, in other environments, have
examined effects of diesel exhaust (particulate) and other air pollutants [91,92];
3.2.3. Arthritis
Early work by Healy and collaborators suggested an effect on shear stress in chondrocytes [93].
This has now been followed by the elegant demonstration that increasing broccoli intake results in
isothiocyanate (e.g., sulforaphane) uptake into the joint, with concomitant changes in the joint [59].
Much other work on anti-inflammatory properties of sulforaphane may ultimately be related to arthritis;
3.2.4. Asthma and Atopic Allergic Responses
A variety of relatively small but significant effects of sulforaphane have been demonstrated in a
number of relatively complex experimental systems [73,92,94–97];
3.2.5. Cancer Biomarkers
A large variety of biomarkers have now been reported following sulforaphane treatment. The cancers
being studied include: Breast [55,98], lung [99]; gastric [100], colo-rectal [101], prostate [79,80,102,103],
skin [75,83,84,104], head and neck [72], and liver [90];
3.2.6. COPD
A 90-subject, three-center RCT was conducted with sulforaphane-rich broccoli sprout extract
in which no effect was seen on patients with advanced COPD. Post-facto reasoning suggested that
the already severely degraded condition of subjects’ airways may well not have permitted for
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responsiveness (Nrf2-related and anti-inflammatory) regardless of the agent used [105]. A follow-up
analysis suggests that there was compartmentalization of anti-oxidant and anti-inflammatory gene
expression in current and former smokers with COPD [106];
3.2.7. CVD
At least three different groups have reported effects that included biochemical markers [107],
blood pressure and flow-mediated dilation [108], and plasma metabolite biomarkers [82,85];
3.2.8. Diabetes, Metabolic Syndrome, and Related Disorders
Many clinical studies from at least three different groups have now been published. They have shown
effects on reduced gluconeogenesis [86], inflammatory markers [109], and insulin resistance [110–112];
3.2.9. General
Extensive measures in a variety of studies have documented upregulation of key chemoprotective
enzymes. To name only a few studies not mentioned elsewhere in this review: [113,114];
3.2.10. Helicobacter Pylori Infection
Our initial observations in vitro and in an animal model [11] have been translated to some
eradication and more importantly, reduction of the levels of H. pylori colonization and gastric
inflammation in some infected individuals [115–117];
3.2.11. NASH/NAFLD
Positive changes in liver function markers have been observed [118] and much interest continues,
based upon encouraging pre-clinical studies;
3.2.12. Neurodegenerative Conditions
Small studies showing effects on GSH levels and mapping GSH elevations to specific brain regions
have generated much excitement [5,81];
3.2.13. Neurodevelopmental Conditions
One successful and highly visible study showing improvement of conditions of autism spectrum
disorder (ASD) following consumption of sulforaphane from broccoli sprouts [87,119] is now being
followed up with at least five studies with ASD subjects, two with schizophrenia, and one with
psychoses. Results of only one of these follow-on studies has published so far [120];
3.2.14. Sickle Cell Disease
Although only a single, small, dose escalation Phase 1 trial has been run, a limited number of
disease-relevant pharmacodynamic endpoints were queried, and safety was evaluated through a
relatively high calculated dose [74].
3.3. Summary of Clinical Studies with Sulforaphane, Glucoraphanin or Mixtures
Table 1 summarizes the published literature of clinical trials conducted with broccoli-based
preparations, sulforaphane and/or glucoraphanin. Also included are clinical trials listed on ClinicalTrials.
gov that are known to be underway. Pending trials are not included. Oral doses that delivered
sulforaphane directly ranged from 9.9 to 847 µmol per person per day (median 100 µmol) and for
glucoraphanin 25 to 800 µmol per person per day (median 190 µmol). The trend towards the use of
higher doses of glucoraphanin versus sulforaphane reflect considerations on the part of study directors
on the limited conversion of glucoraphanin to sulforaphane in the absence of exogenous myrosinase in
beverage or dietary supplement preparations.
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The harsh taste (a.k.a. back-of-the-throat burning sensation) that is noticed by most people
who consume higher doses of sulforaphane, must be acknowledged and anticipated by investigators.
They must make accommodations for what some subjects may consider a highly objectionable taste.
This is particularly so at the higher limits of dosing with sulforaphane, and not so much of a concern when
dosing with glucoraphanin, or even with glucoraphanin-plus-myrosinase. It is this harsh or burning
sensation that has led in part to the characterization of the glucosinolate-myrosinase-isothiocyanate
system as “the mustard oil bomb” [121]. This should not, however, be confused with the bitter
descriptor leveled at most brassica vegetables and moringa, that appears to have more to do with the
TAS2R class of taste receptors.
The presence and/or enzymatic production of levels of sulforaphane in oral doses ranging above
about 100 µmol, creates a burning taste that most consumers notice in the back of their throats
rather than on the tongue. This prevents some from consuming broccoli/sulforaphane preparations.
Higher doses of sulforaphane lead to an increased number of adverse event reports, primarily nausea,
heartburn, or other gastrointestinal discomfort [44,67,87,119,122]. We have conducted scientifically
guided studies to mask or distract consumers from that very distinctive taste, and to facilitate the
development of proper placebos [122,123].
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Table 1. Summary of Clinical Trials with Broccoli, Glucoraphanin or Sulforaphane.
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7 Results Ref
1998 Shapiro Healthy x x x x
250 g fresh broccoli (180 µmol
GR) or 144 µmol GS or 118
µmol isothiocyanates (ITC)
6 180 µmol GR 2.57 (GR)
PK following GR or GS or ITC
ingestion: Reproducibility and
dose-dependence as measured in
urine using the cyclocondensation
[26]
2000 Conaway Healthy x x x
200 g fresh or steamed
broccoli w/ 220 and 200 µmol
ITCs respectively
12
220 & 200 µmol of total ITCs
(measured and assumed to
be primarily SF)
3.14/2.86 (SF)
Bioavailability of ITCs from fresh
broccoli is greater than that from
cooked broccoli
[124]
2002 Ye Healthy x x x 200 µmol SF 4
broccoli extracts containing
predominantly SF; 200 µmol
total ITC
2.86 (SF)
Development of a sensitive and
specific method for quantifying
levels of ITC and their metabolites
in human plasma, serum, and
erythrocytes
[56]
2004 Murashima Healthy x x 100 g fresh broccoli sprouts/dx 7 d 12
we calculate a maximum of
500 µmol GR/d 7.1 (GR)
Improvement of lipid metabolism;
HDL cholesterol increased
significantly only among females
[107]
2004 Walters Healthy x x
250 g broccoli or brussels
sprouts (cooked), per day for
12 days
20 (est.) ca. 25 µmol GR 0.36 (GR) Induced metabolism of PhIP inhumans [101]
2005 Gasper Healthy x x
100 g florets from standard
broccoli and
high-glucosinolate broccoli,
one dose
16
150 mL of 107.5 or 345.8 µM
“sulforaphane metabolites”
broccoli soup
0.23 or 0.74 (SF) GSTM1 genotypes have significanteffect on the SF metabolism [53]
2005 Kensler Healthy x x x
broccoli sprout extract (BSE)
containing 400 umol or <3
umol GR (placebo), daily for
2 weeks.
200 <3 µmol GR/day or 400 µmolGR/day 0.043/5.71
Decreased urinary excretion of
dithiocarbamates and
aflatoxin-DNA adducts and trans,
anti-phenanthrene tetraol in urine
by broccoli sprout glucosinolates.
[90]
2004 Galan
Helicobacter
pylori infected
adults
x x x x 14, 28, or 56 g broccolisprouts 2x/d x 7 days 7 up to 280 µmol GR/day 1, 2, 4 (GR)
7 of 9 patients were stool antigen
negative immediately after the
completion of therapy and six
remained negative at day 35.
[115]
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7 Results Ref
2006 Shapiro Healthy x x x
BSE containing 25 µmol GR,
100 µmol GR, or 25 µmol SF,
3x/d x 7 d
12 75 & 300 µmol GR/d; 75 µmolSF/d
1.97 & 4.29 (GR);
1.07 (SF)
Cumulative excretion of SF
metabolites similar regardless of
GR dose, & much higher when
taking SF; diurnal cycling obser.
[61]
2007 Cornblatt Reductionmammaplasty x x
SF-rich beverage (containing
200 µmole SF) 8 200 µmol SF once 2.86 (SF)
Measured serum and mammary
tissue levels of SF metabolites [55]
2007 Gasper Healthy x x
“standard” and “HG”
broccoli florets microwaved
gently to make soup
16 683 and 2296 µM SFmeasured 1.42/4.92 (SF)
Consumption of high glucosinolate
broccoli resulted in up-regulation
of several xenobiotic metabolizing
genes in gastric mucosal tissue
[100]
2007 Myzak Healthy x x 68 g broccoli sprouts(approximately 105 mg SF) 3
847 µmol SF if all converted
from GR using author′s
estimate; 136 µmol SF using
our estimate
12.1 (auth)/1.9
(us) (SF)
HDAC activity was significantly
inhibited in PBMC [125]
2007 RungapamestryHealthy x x x x x
150 g lightly cooked broccoli
or fully cooked broccoli or a
broccoli seed extract with
added mustard seed
12 62 & 71.7 µmol GR/d or 2.7
µmol SF 0.89/1.0 (GR)
Estimated yield of SF was ~ 3-fold
higher after consumption of lightly
cooked broccoli than fully cooked
broccoli. Meal matrix did not
significantly influence the
hydrolysis of GR and its excretion
as SF
[126]
2008 Traka
Diagnosed
with
high-grade
prostatic
intraepithelial
neoplasia
(PIN)
x x 150 g broccoli /d 22 79.3 µmol GR/d 1.13 (GR)
Showed complex change in
signaling pathways associated
with inflammation and
carcinogenesis: Modified by
GSTM1 genotype in broccoli
feeding group
[79]
2008 Vermeulen Healthy x x x 200 g crushed raw or cookedbroccoli 8
9.92 µmol SF or 61.4 µmol
GR/d
0.14 (SF)/0.88
(GR)
10x greater bioavailability of SF w/
crushed, raw vs. microwaved
broccoli
[127]
2009 Hanlon Healthy x x
300 mL of homogenized raw
broccoli w/ 3.9 mg SF, for 10
consecutive days
6 22 µmol SF/d 0.31 (SF)
Repeated intake of broccoli had no
impact on the pharmacokinetic
behavior or plasma levels of SF
[128]
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7 Results Ref
2009 Riedl Healthy x x
150, 175, and 200 g broccoli
sprout homogenate mixed
with daikon sprouts
homogenate, once daily for 3
days
65 75 µmol/87.5 µmol /100 µmolSF/day (est)
1.07/1.25/1.43
(SF)
Increased Phase II enzyme
expression in nasal lavage cells
occurred in a dose-dependent
manner
[76]
2009 Riso
Healthy (10
smokers and
10
nonsmokers)
x x 200 g blanched broccoli x 10 d 20
200 µmol total ITC
equivalents (presumed by us
to be </=50 µmol GR
0.71 (GR)
↓ Strand breaks with broccoli diet
in smokers/nonsmokers. ↓
oxidized purines only in smokers.
Broccoli intake did not modify
HDAC activity or IGF-I serum
levels
[99]
2009 Yanaka H.pylori–infected x x x
GR-rich broccoli sprouts for 8
weeks 47 420 µmol GR (+ mryrosinase) 6 (GR)
Decreased levels of urease
measured by the urea breath test
and H. pylori stool antigen;
decreased serum biomarkers of
gastric inflammation
[116]
2010 Christiansen
Hypertensive,
without
diabetes &
with normal
cholesterol
x x x 10 g dried broccoli sprouts/d 40 259 µmol GR (measured) 3.7 (GR)
Daily ingestion of 10 g dried
broccoli sprouts does not improve
endothelial function in the
presence of hypertension
[108]
2011 Bahadoran Type 2disbetes x x x
5 g or 10 g broccoli sprouts
powder (BroccoPhane) said
to contain SF, daily for 4
weeks (we have assayed
previously and found this
not to be the case)
81
113 or 225 µmol SF/d based
only on manufacturer′s
claims
1.61/3.22 (SF)
Significant decrease in
malondialdehyde, oxidized low
density lipoprotein cholesterol,
oxidative stress index & significant
increase in total serum antioxidant
capacity
[111]
2011 Clarke Healthynon-smokers x x x x x x
68 g fresh broccoli sprouts or
supplement purported to
contain GR + Myr from 3 g
dried broccoli sprouts
24 ~ <220 µmol GR 3.1 (GR)
Consumption of fresh sprouts with
active myrosinase provides 5x
more bioavailable SF; SF and
erucin metabolites are readily
interconverted
[129]
2011 Egner Healthy x x x x
SF-rich beverage (containing
150 µmole SF) or GR-rich
beverage (containing 800
µmole GR) daily for 7 days.
69 800 µmol GR/d, 150 µmol SF
/d
11.4 (GR)/2.14
(SF)
Bioavailability of SF (measured as
urinary metabolites) was
substantially greater with the
SF-rich than GR rich beverage
[63]
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7 Results Ref
2011 Healy Healthy x x x 561 mg BSE powder (200
µmol GR) 4 200 µmol GR/d 2.86 (GR)
Consumption of BSE showed
inactivation of urinary MIF
tautomerase activity in urine
[113]
2011 Hauder
Healthy male
non-smoking
(50-82 y.o.)
x x
200 g of blanched, regular or
selenium-fertilized broccoli,
daily, for 4 weeks
76 broccoli contained either 133or 226 µg/g of GR 0.87 or 1.48 (GR)
Dietary intake of
selenium-fertilized broccoli
increased serum selenium
concentration, but affected neither
glucosinolate concentrations in
broccoli nor their metabolite levels
in plasma and urine compared to
regular broccoli.
[130]
2012 Bahadoran Type 2diabetes x x x
10 g or 5 g broccoli sprouts
powder (BroccoPhane) said
to contain SF, daily for 4
weeks.
81
113 or 225 µmol SF/day based
only on manufacturer′s
claims
1.61/3.22 (SF)
Consumption of 10 g/d resulted in
a significant decrease in serum
insulin concentration and
HOMA-IR
[112]
2012 Cramer Healthy x x x x
2 g GR powder or 42 g fresh
broccoli sprouts/d; once a
week for 4 weeks
4
120 µmol GR/d or 70 µmol
GR (fresh sprouts with active
myrosinase)/d
1.71/1 (GR)
Adding fresh broccoli sprouts (as a
source of myrosinase) to GR
synergistically enhanced
absorption and excretion
[131]
2012 Fahey Healthy x x x 200 µmol GR 131 200 µmol GR 2.86 (GR)
Extreme inter-individual range of
conversion efficiencies (1–40% of
administered dose of GR)
attributed to differences in
microbiomes as well as circadian
rhythm; within-individual
differences were less pronounced
[65]
2012 Kensler Healthy x x x x
Cross-over design: GR-rich
beverage (800 µmol GR)→
SF-rich beverage (150 µmol
SF)/SF-rich beverage (150
µmol SF)→GR-rich beverage
(800 µmol GR)
50 800 µmol GR/day, 150 µmolSF /d
11.4 (GR)/2.14
(SF)
Statistically significant increases in
the levels of excretion of
glutathione-derived conjugates of
benzene and acrolein, but not
crotonaldehyde in groups
receiving SF-rich, GR-rich
beverages or both compared to
preintervention values
[77]
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7 Results Ref
2012 Mirmiran Type 2diabetes x x x x
5 or 10 g/d of BroccoPhane
powder (BSP), reported to be
rich in SF, – daily x 4 wks (we
have assayed previously and
found this not to be the case)
81
113 or 225 µmol SF/day based
only on manufacturer′s
claims
1.61/3.22 (SF)
Sera of BSP treatment groups
showed ↓ hs-CRP, and
non-significant ↓ IL-6 and TNF-α
[110]
2012 Saha Healthy x x x
Broccoli soups produced
from fresh or frozen broccoli
florets
18
4.16 mg SF/serv (23.5 µmol)
or 18.6 mg GR/serv. (42.7
µmol)
0.33 (SF)/0.61
(GR)
SF bioavailability was~10x higher
in fresh compared to frozen
broccoli
[132]
2013 Armah 10-y CVD riskprofile x x
400 g standard or “HG”
broccoli or placebo vegetable
(peas) for 12 wk
54 6.9 or 21.6 µmol GR/g dry wtbroccoli 1.48/4.63 (GR)
No significant differences on
markers of CVD risk [82]
2013 Meyer Healthy x x
SF-rich homogenate prepared
from 200 g BroccoSprouts
(assayed for SF) daily for 3
consecutive days
12 100 µmol SF/day (our est.) 1.43 (SF)
Homogenate significantly
increased secretory leukocyte
protease inhibitor levels in nasal
lavage fluid
[94]
2013 Poulton Healthy x x
BSE (450 µmol SF/d x 7 d
delivered in cheese-based
soup
23 450 µmol SF/d 6.43 (SF) No effect on CYP3A4 activity [44]
2014 Bahadoran
Type 2
diabetic with
H. pylori
infection
x x x
6 g/d of Cyvex broccoli
sprouts powder (BSP),
reported to be rich in SF, (we
have assayed previously and
found this not to be the case),
daily, in combination with
other drugs, for up to 28 d
86 Maximum possible is 135
µmol SF/day 1.93 (SF)
BSP ↓ H. pylori load in diabetic
patients, but no effect on gastric
inflammatory markers
[117]
2014 Baier Healthy x x 34, 68 or 102 g Broccolisprouts 8
170, 340, and 680 µmol
GR/day 2.4/4.8/9.6 (GR)
Dose dependent elevation in LTR
(long terminal repeats) mRNA &
histone acetylation in circulating
leukocytes
[133]
2014 Egner Healthy x x x x
broccoli sprouts beverages
containing GR-rich and
SF-rich powders (600 µmol
GR + 40 µmol SF), daily, for
150 days
267 600 umol GR/day + 40 µmolSF/day
8.57 (GR) + 0.57
(SF)
Significant increases in the levels
of excretion of the
glutathione-derived conjugates of
benzene and acrolein in urine in
broccoli sprout beverage treatment
group
[78]
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7 Results Ref
2014 Heber Healthy x x x 1.25 g BSE suspended in juice(100 µmol SF/d x 4 d) 29 100 µmol SF/d 1.43 (SF)
Subjects challenged w/ repeated
nasal diesel exhaust particles:
WBC decreased 54% by daily BSE
[91]
2014 Noah Healthy x x smokers/nonsmokers -broccoli sprout homogenate 16/35 100 µmol SF/d (est) 1.43 (SF)
Post BSH, live attenuated influenza
virus-induced inflammatory
markers reduced; NQO1 increased,
in smokers but not non-smokers
[92]
2014 Singh
♂,13–27 y.o.
with moderate
to severe
Autism
Spectrum
Disorder
x x x 50 - 150 µmol SF/d x 18weeks; dosed by BW 44 50 µmol SF/d - 150 µmol SF/d 0.71 - 2.14 (SF)
SF showed substantial declines
(improvement of behavior) in
Aberrant Behavior Checklist and
Social Responsiveness Scale scores
[87]
2015 Alumkal Prostatecancer x x x
SF-rich broccoli sprout
extract; 200 µmol/d x 20
weeks
20 200 µmol SF/d 2.86 (SF) Did not lead to ≥50% PSA declines [103]
2015 Armah
10 Year
cardiovascular
risk profile of
between 10
and 20%
x x
400 g standard or “HG”
broccoli or placebo vegetable
(peas) for 12 wk
130 6.9 or 21.6 µmol GR/g dry wtbroccoli 1.48/4.63 (GR)
High glucoraphanin (HG) broccoli
diet ↓ plasma LDL-C more than
standard broccoli
[85]
2015 Atwell
Abnormal
mammograms;
scheduled for
breast biopsy
x x x
broccoli seed extract
containing GR (BroccoMax);
[we have assayed previously
and found the myrosinase to
be inactive and the GR titer
to not be as represented], 2
capsules, 3x/d, x 2-8 wk
54 180 mg GR/day (= 413 µmolGR/d) 5.9 (GR)
↓ PBMC HDAC activity;
pre-to-post changes in Ki-67 and
HDAC3; NSD in tissue biomarkers
between placebo and treatment
group
[98]
2015 Atwell Healthy x x x x x
fresh broccoli sprouts
(containing 200 µmol GR) or
SF-rich BSE (containing 200
µmol SF) daily, consumed
every 12 h.
20 200 µmol SF/d; 200 µmolGR/d
3.33 (SF); 3.33
(GR)
3 x higher SF metabolite levels in
plasma and urine in sprout
consumers compared to SF-rich
BSE consumers
[57]
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7 Results Ref
2015 Brown Moderateasthma x x x
440 mg SF-rich BSE (100
µmol SF/d x 14 d) 45 100 µmol SF/d 1.43 (SF)
Individuals in whom SF treatment
enhanced the forced expiratory
volume response to methacholine,
had increased expression of
Nrf2-regulated antioxidant and
anti-inflammatory genes in
peripheral blood mononuclear
cells: SF treatment resulted in
significant reduction in airway
resistance and increased small
airway luminal area
[73]
2015 Chang H. pylori x x x SF capsule twice daily for 4weeks. 67
2 mg SF/day (11.3 µmol SF/d)
[we do not trust this
company′s representation of
dose]
0.16 (SF)
No significant difference in urea
breath test values or ammonia
concentration; SF did ↓ gastric
mucosal malondialdehyde but not
glutathione levels
[134]
2015 Cipolla
Prostate
cancer
patients post-
radical
prostatectomy
x x x
SF tablets (2 tablets
containing 10 mg stabilized
SF extracted from broccoli
seeds, 3 times a day) for 6
months
78 60 mg SF /day (339 µmolSF/d) 4.83 (SF)
Decreased prostate-specific
antigen (PSA) levels [102]
2015 Fahey Healthy x x x x x x
50, 69, 100, 200, 230 µmol GR
in various dose forms
including comparing
commercial tablets to
investigator-prepared
materials and GR with active
myrosinase
20 50, 69, 100, 200 & 230 µmolGR
0.7/1.0/1.4/2.9/3.3
(GR)
Inter- and intra-individual
variabilities, when GR delivered in
teas, juices, or gelatin capsules;
established effect of adding active
myrosinase to the “dose”
[68]
2015 Kikuchi
Diagnosis of
fatty liver
with elevated
liver function
markers
x
3 broccoli sprout capsules
(containing 30 mg GR) for 2
months
55 69 µmol GR/d 1 (GR) ↓ serum ALT, AST, γ-GTP [118]
2015 Medina Healthy x x 30 g or 60 g of broccolisprouts 24
~117 or 234 µmol GR
(measured)/d as well as
much smaller amounts of SF
(measured)
1.67/3.34 (GR)
Broccoli sprouts modulated
excretion of biomarkers linked to
inflammation and vascular
reactions without exerting a
significant influence on the
oxidation of phospholipids
[135]
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7 Results Ref
2015 Shiina Schizophrenia x x x 30 mg GR/d x 8 weeks 10 30 mg GR/d (69 µmol GR/d) 1 (GR)
Mean score in the Accuracy
component of the One Card
Learning Task increased
significantly after the trial.
[136]
2015 Ushida Healthy x x x
dried broccoli sprout
capsules (3 or 6 capsules rich
in GR)
21 68.7 or 137.4 µmol GR/day 0.98/1.96 (GR)
Serum activities of GST and NQO1
were dose-dependently and
synchronously elevated
[114]
2016 Bauman Healthy x x
150 µmol SF oral swallowed
or held in mouth, or 600
µmol GR swallowed
10 8.57 (GR)/2.14(SF)
Clinical support for good mucosal
bioactivity and pharmacodynamic
activity
[72]
2016 Doss Sickle celldisease (SCD) x x x
broccoli sprout homogenate
(BSH) made from 50, 100, or
150 g fresh BroccoSprouts
16
250, 500, or 750 µmol GR
[calculated maximum
delivery]
3.6/7.1/10.7 (GR)
Homogenate is safe in SCD
subjects; only modest changes in
NRF2-mediated gene expression
[74]
2016 Duran Healthy x x
Homogenate prepared from
111 g BroccoSprouts once
daily for 3 days
16 555 µmol GR/day 7.9 (GR)
On last treatment day, subjects
were exposed to ozone with
intermittent moderate exercise to
induce airway inflammation:
Homogenate did not induce
expression of antioxidant genes in
blood and nasal epithelial cells
[97]
2016 Müller Healthy x x
Broccoli sprout homogenate
shake prepared from 200 g
sprout (about 100µmol of SF
per dose) or alfalfa sprout
homogenate for control, for 4
days
42 100 µmol SF/day (est.) 1.43 (SF)
BSH supplementation increased
live attenuated influenza
virus-induced granzyme B
production in NK cells compared
to control
[96]
2016 Sudini Asthma x x
100 g fresh broccoli sprouts
(BS) /d or 100 g of alfalfa
sprouts (placebo) x 3
consecutive d
40
no GR or SF measurements
made or imputed; max poss.
expected to be 500 µmol
GR/d
7.14 (GR)
No induction of cytoprotective
antioxidant genes in either PBMCs
or nasal epithelial cells or ↓
oxidative stress and inflammatory
markers in urine and serum; no
improved lung function.
[95]
2016 Wise COPD x x x
SF extracted from broccoli
sprouts (25 µmol/150 µmol)
daily for four weeks
89 25 µmol SF/d; 150 µmol SF/d 0.36 & 2.14 (SF)
SF did not stimulate expression of
Nrf2 target genes or have an effect
on levels of other anti-oxidants or
markers of inflammation.
[105]
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7 Results Ref
2017 Axelsson
Diabetics
(well
regulated, and
dysregulated)
x x x 5410 ppm of SF x 5 g/d 97 153 µmol SF/d 2.18 (SF)
SF reduced fasting blood glucose
(hepatic gluconeogenesis) &
glycated hemoglobin (HbA1c) in
obese patients with dysregulated
T2D
[86]
2017 Davidson Osteoarthritis x x 100 g high glucosinolate (HG)broccoli/d x 14 d 40 180 µmol GR/d 2.57 (GR)
ITCs detected in synovial fluid of
HG group, but not the low
glucosinolate group.
[59]
2017 Fahey Healthy x x x x x 94.4 µmol SF/d or 200 µmol
α-cyclodextrin enrobed SF/d 10 94.4 µmol SF/d 1.35 & 2.86 (SF)
PK and tolerance of α-cyclodextrin
enrobed SF (for theoretical
stabilization) was compared to that
of SF along, in the commercial
“stabilized SF” product
Prostaphane™
[66]
2018 Sedlak Healthy x x x 100 µmol SF/d x 7 d taken in2 gel caps per day 9 100 µmol SF/d 1.43 (SF)
Correlation between blood and
thalamic GSH post- and pre-SF
treatment ratios and a consistent
increase in brain GSH levels (7
Tesla MRI)
[81]
2018 Tahata Melanoma x x x
Broccoli sprout extract-SF
standardized for 50, 100, or
200 µmol SF for 28 days
17 50 µmol /100 umol/200 µmolSF/day
0.71/1.43/2.86
(SF)
Oral BSE-SF is well tolerated at 50,
100, and 200 µmol /day attaining
blood plasma and skin biopsy
levels reasonable for
pharmacodynamic action
[104]
2018 Bent
Children with
ASD and
related
neurodevelopmental
disorders
x x
6 to 15 Avmacol tablets (222
µmol GR to 555 µmol GR)
daily for 12 weeks,
depending on BW
15 222 umol GR/day - 555 umolGR/day 3.17 - 7.93 (GR)
Mean scores on both symptom
measures showed improvements
(decreases) over the study period,
which was correlated with urinary
metabolites
[120]
2018 Housley Healthy x x fresh broccoli sprouts(containing 200 µmol GR) 10 200 µmol GR/d 2.86 (GR)
Untargeted metabolomic screen of
human plasma following
consumption of fresh broccoli
sprouts
[137]
2018 Okunade Healthy x x x 200 g raw, cooked broccoli ±1 g mustard powder 12
62, 32, or 257 µmol GR/d
based on conversion of
author′s dry wt., to (our)
fresh wt. basis
0.88/0.45/3.7
(GR)
↑ urinary SF-NAC when cooked
broccoli consumed with mustard
powder
[138]
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7 Results Ref
2018 Sivapalan Healthy x x
300 g Myb28B/B (standard)
or Myb28B/V (Beneforte) or
Myb28V/V broccoli soup;
single dose
10 84, 280, or 452 µmol GR/d 1.2/4.0/6.5 (GR)
Three different Myb28 genotypes
of broccoli related with delivery of
sulforaphane to the systemic
circulation.
[52]
2019 Chartoumpekis Healthywomen x x x x
Broccoli sprouts beverages
containing GR-rich and
SF-rich powders (600 µmol
GR + 40 µmol SF), daily, for
150 days
45 600 umol GR/day + 40 µmolSF/day
8.57 (GR) + 0.57
(SF)
Measurement of thyroglobulin,
TSK, free thyroxine, and others [62]
2019 Lopez Chillon Healthy,overweight x x
30 g/d of fresh broccoli
sprouts, for 10 wks followed
by 10 wks of washout
40 117 µmol GR/d (measured) 1.67 (GR) Reduced IL-6 and CRP followingbroccoli sprout consumption [109]
2019 Chen Healthy x x x x
Broccoli sprout beverage
(contained GR and SF), full
dose or half dose or fifth dose,
daily for 10 consecutive days
170
600 µmol GR + 40 µmol SF or
300 µmol GR + 20 µmol SF or
125µmol GR + 8 µmol SF/day
600/40, 300/20,
or 125/8 (GR +
SF)
Benzene mercapturic acids in urine
was increased in high dose treated
group, but not in half dose and
one-fifth dose
[69]
2019 Fahey Healthy x x x
Avmacol - (GR with active
myrosinase; 6 tablets211 µ,
mol GR, single dose, n=20);
and 8 Avmacol tablets (369
µmol GR), on 4 separate days,
enteric-coated and not-coated
20 & 16 211 and 369 µmol GR/day 3.01/5.27 (GR)
Gastric acidity somewhat
attenuates activity of oral
myrosinase reducing conversion of
GR to SF, and thus SF
bioavailability; cytoprotection,
antioxidant and detoxification
gene expression increased with
increasing SF bioavailability.
[67]
2019 Traka
Men with low
to intermed.
risk prostate
cancer
x x broccoli 61 72 - 492 µmol GR 1 - 7 (GR)
Affected gene expression in the
prostates of men under active
surveillance, consistent with
prevention
[80]
2020 Bauman
Head and
neck cancer
survivors
x x Avmacol 50 or 100 mg GR(115 or 230 µmol GR) 36 115 or 230 µmol GR 1.6-3.3
Ongoing; “Preventing Recurrence
in Patients With Tobacco-Related
Head and Neck Squamous Cell
Cancer”
NCT03182959
2020 Kim
H. pylori
infected adults
(18-75 y.o.)
x broccoli sprout extract 360 –
Ongoing; “The Effect of Broccoli
Sprout Extract and Probiotics for
Eradication of Helicobacter Pylori”
NCT03220542
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7 Results Ref
2020 Bauman Smokers x x Avmacol - 4 or 8 tablets/d 61 (our calculation) ~ 138 and275 µmol GR 2.0/4.0 (GR)
Ongoing; Decreasing Toxicity in
Heavy Smokers NCT03402230
2020 Dickerson
Adults (18-65
y.o.) with
schizophrenia
x x x Avmacol 64 weight-based, about 1.4
µmol/kg BW 1.42 (GR)
Ongoing; amelioration of
symptoms of schizophrenia NCT02810964
2020 Hua/Davis
Children (3-15
y.o.) on the
autism
spectrum
x x x Avmacol 110 –
Ongoing; amelioration of
symptoms of autism spectrum
disorder (ASD)
NCT02879110
2020 Hua/Davis
Adults with
1st episode or
early onset
schizophrenia
x x x Avmacol 180 – Ongoing; amelioration ofsymptoms of schizophrenia NCT02880462
2020 Johnson
Young adults
(13-30 y.o.), on
the autism
spectrum
x x x Avmacol 45 weight-based, about 1.5
µmol/kg BW 1.47 (GR)
Ongoing; amelioration of
symptoms of autism spectrum
disorder (ASD)
NCT02677051
2020 Li
Veterans with
allergic
rhinitis
x x broccoli sprout extract 475
Phase 2 RCT; BSE paired
with fluticasone or normal
saline spray
– Ongoing; “Effects of BroccoliSprout Extract on Allergy Rhinitis”
NCT
0288
5025
2020 Politte
Young men
(13-30 y.o.), on
the autism
spectrum
x x x Avmacol 48 weight-based, about 1.4
µmol/kg BW 1.4 (GR)
Ongoing; amelioration of
symptoms of autism spectrum
disorder (ASD)
NCT
0290
9959
2020 Tex Tech
Doxirubicin-naïve
women with
breast cancer
x x Avmacol (2 - 8 tablets/d) x 12weeks; weight based 70 68.8 - 275 µmol GR 1 - 3.9 (GR)
Ongoing; “Effects of the SF on
doxorubicin-associated cardiac
dysfunction”
NCT
0393
4905
2020 Wang Adults at riskfor psychosis x x x
Chinese commercial “GR +
Myros. “ supplement
(Zhiyinguosu)
300 52 wk, daily about 411 µmolGR with active myrosinase 5.9 (GR)
Ongoing; 1◦ planned outcome –
conversion to psychosis
NCT
0393
2136
2020 Wu
1st episode or
early onset
schizophrenia
(SZ)
x x Avmacol 180 –
Ongoing; “A 6-month Study to
Evaluate SF add-on Effects in
Treatment of SZ”
NCT
0288
0462
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7 Results Ref
2020 Yuan FormerSmokers x x Avmacol 72 120 µmol 2x/d 3.4 (GR)
Ongoing; lung cancer prevention
in former smokers
NCT
0323
2138
2020 Zandberg
Head & neck
cancer
patients
post-curative
treatment
x x x
Avmacol; escalating daily
doses, from 2 to 4 to 8 tabs
per day for a month each
36 69, 138, or 275 µmol GR 1/2/3.9 (GR) Ongoing
NCT
0326
8993
2020 Zimmerman
Children (3-12
y.o.), on the
autism
spectrum
x x x Avmacol 60 weight-based, about 2.2
µmol/kg BW 2.2 (GR)
Ongoing; amelioration of
symptoms of autism spectrum
disorder
NCT
0256
1481
1 Year published, if published results exist. In cases where it appears that the trial is well underway and/or when we have queried the P.I., we have included “pending” trials that are
listed on clincaltrials.gov. In such cases “year pub′d” is arbitrarily given as 2020. 2 Compound(s) delivered are either sulforaphane (SF), glucoraphanin (GR) or GR with added, active,
myrosinase enzyme (GR + Myr) 3 Delivery formats are: Tablets or capsules (gelatin or vegan/vegetable gel-caps) - “Tabs/caps”; powders that may be added to juices, water, or other food
products - “Powder/Other”; fresh broccoli or broccoli sprouts, either cooked in various ways as indicated, or raw – “Fresh” 4 When products are commercially supplied, there is reason for
concern over use solely of manufacturers′ reported compound (GR or SF) titer. Many investigators appropriately measure compound concentration themselves and where we have
included studies that do not do so, we have attempted to so note. 5 As above, we have attempted to note cases where titer is suspect and in some cases we have tested the products used
(purchased commercially ourselves, so likely other “lots”), and found them to be vastly different in content or quality, from indications made in the sales literature for those products. Other
abbreviations used herein – BSE, broccoli sprout extract; BSP, broccoli sprout powder; GS, glucosinolate; ITC, isothiocyanate; ASD, autism spectrum disorder; SZ schizophrenia; RCT,
randomized control trial 6 Assumptions made in calculations are that if fed homogenized fresh broccoli or broccoli sprouts, they were getting SF and it was in many cases impossible to even
guess how much, if any. Thus, if given fresh broccoli or broccoli sprouts and titer not provided in reference, our assumption is that sprout titer was ≤5 µmol GR/g sprouts, and subjects were
ingesting “GR + Myr”. 7 In cases where the authors did not indicate dosage in µmol/kg body weight (BW), we have made those calculations using the a priori assumption of a 70 kg BW.
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4. Challenges Ahead
4.1. Plants Versus Discrete Isolates: Foods vs. Supplements
As an ultimate public health paradigm, eating plants directly, with or without cooking or minimal
processing, must be the solution in most of the world. The wealthiest regions can afford supplements
as preventive interventions. Attempting to turn a chemopreventive approach into a pharmaceutical
strategy would be foolhardy, but to the extent that sulforaphane is proven to have curative or therapeutic
properties, this could be a direction in which to turn. From the perspective of designing and conducting
clinical studies to demonstrate preventive efficacy, many issues come to bear on the subject. Though
we have dealt with them [65,139,140], certain of them bear repeating:
4.1.1. First
If it is indeed plant foods that will be the ultimate delivery vehicle, then food companies which
will share in an enormous upside to successfully enhanced health-span, must bear some of the costs of
conducting these trials. Though much has been made of the size and lobbying muscle of “big pharma”,
(roughly a trillion dollar industry worldwide), the food sector of the economy in the USA alone is now
valued at about $1.1 trillion [141].
4.1.2. Second
Standardization of dose delivery is extremely difficult when conducting clinical studies with foods.
As sulforaphane gains scientific credibility as a preventive phytochemical, the clinical studies aiming
to determine how, how much, for how long, and how to deliver and measure it, will by definition grow
larger, longer, and more sophisticated. Perhaps there will come a time when foods such as broccoli will
be labeled with variety name (e.g., like the maddening little stickers on apples) and glucoraphanin titer
to enhance the consumer’s ability to make direct health-span purchasing choices. In the meantime, the
clinical studies that we have performed with broccoli and broccoli sprouts have already strained the
academic system to the breaking point [142]. The food industry needs to step up.
We and others have switched to the use of sulforaphane-containing or sulforaphane-generating
supplements as discussed herein. However, the use of commercial supplements is fraught with dangers
since there are many poor supplements and many unscrupulous supplement purveyors [143,144].
Robust quality control is essential. Thus, better industry monitoring and regulation, as well as rigorous
validation by investigators, of the labeled “doses”, is critical. One cannot for the foreseeable future
trust that what appears on the label is an accurate representation of “dose” (and sometimes plant
entity), and in Table 1 we have indicated clinical studies in which label results have been used rather
than making dose measurements prior to or during intervention.
4.1.3. Third
There must be clinician buy-in to the concept that “thy food is thy medicine, and thy medicine is
thy food”. It has been attributed, perhaps fallaciously, to Hippocrates, but regardless of its origin, the
physicians who are Hippocrates’ intellectual descendants, have not risen to take the bait. They have
instead taken the bait of big pharma, hook-line-and-sinker, and it is threatening to sink our economy.
Pharmaceuticals most certainly have their place, but we must recruit the physicians in our society,
whom people still trust in matters of their critical and preventive care, to more firmly place at least one
foot in the dietary side of the aisle.
4.2. Optimizing the Definition of Dose
Several key challenges in the design of clinical chemoprevention trials, especially food-based
trials, are the selection of the dose, formulation, and dose schedule of the intervention material. Dose
schedule is typically delineated by the convenience of a daily schedule and knowledge of the short
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biological half-life of sulforaphane. The other factors are less circumscribed. Selection of dose is
complicated by the very different bioavailability of sulforaphane when administered in the precursor
form of glucoraphanin and when given as sulforaphane itself, as discussed earlier. Figure 4 summarizes
our experiences from four clinical trials conducted in Qidong, China with broccoli-based interventions
enriched with glucoraphanin, sulforaphane, or both.
Molecules 2019, 24, x FOR PEER REVIEW 2 of 37 
 
biological half-life of sulforaphane. The other factors are less circumscribed. Selection of dose is 
complicated by the very different bioavailability of sulforaphane when administered in the precursor 
form of glucoraphanin and when given as sulforaphane itself, as discussed earlier. Figure 4 
summarizes our experiences from four clinical trials conducted in Qidong, China with broccoli-based 
interventions enriched with glucoraphanin, sulforaphane, or both.  
 
Figure 5. Urinary excretion of sulforaphane metabolites (“internal dose”) per 24 h following an initial 
dose with different broccoli sprout preparations from intervention studies conducted in Qidong 
China [63,77,78]. All analyses were conducted by isotope dilution mass spectrometry. Values are the 
sum of sulforaphane, sulforaphane-cysteine and sulforaphane-N-acetylcysteine for each participant. 
Box plots are median and 5% and 95% confidence intervals. GR 800 was a beverage prepared from a 
hot-water extract of 3-day old broccoli sprouts that was lyophilized, and then reconstituted in mango 
juice and water to deliver 800 μmole glucoraphanin (GR); SF 150 was the hot-water extract cooled to 
room temperature, treated with daikon to deliver myrosinase, then lyophilized and later reconstituted 
in mango juice and water to deliver 150 μmol of sulforaphane (SF). GR600 + SF 40 were beverages 
reconstituted in pineapple juice, lime juice and water from their lyophilized powders to deliver a dose 
of 600 μmol of GR and 40 μmol SF. In addition to beverages, a study was conducted with a commercial 
dietary supplement formulated as tablets constituted from lyophilized broccoli sprouts and finely 
milled broccoli seeds to provide glucoraphanin (75 and 150 μmol) in the presence of myrosinase. 
In a cross-over design study we observed recoveries of excreted sulforaphane metabolites 
(principally sulforaphane-N-acetylcysteine) to be about 5% when a glucoraphanin-rich beverage was 
administered with a range of 1 to 45% but about 70% with a much narrow range of inter-individual 
variation when a sulforaphane-rich beverage was used [68]. Thus, bioavailability changes 
dramatically as a function of the source material – precursor or bioactive. Some of our subsequent 
studies used blends of sulforaphane- and glucoraphanin-rich preparations to improve bioavailability 
together with tolerability and to examine dose-response relationships [69,78]. Higher intake was 
achieved, but with little impact on inter-individual variability. Formulation, which in turn reflects 
how broccoli sprout extracts are prepared (e.g., with or without exogenous myrosinase-catalyzed 
hydrolysis of glucoraphanin), strongly affects bioavailability. Using a dietary supplement 
formulation of glucoraphanin plus myrosinase (Avmacol®) in tablet form, we observed a median 20% 
bioavailability with greatly dampened inter-individual variability. Fahey et al., [67] have observed 
approximately 35% bioavailability with this supplement in a different population. Thus, reporting of 
Figure 4. Urinary excretion of sulforaphane metabolites (“internal dose”) per 24 h following an
initial dose with different broccoli sprout preparations from intervention studies conducted in Qidong
China [63,77,78]. All analyses were conducted by isotope dilution mass spectrometry. Values are the
sum of sulforaphane, sulforaphane-cysteine and sulforaphane-N-acetylcysteine for each participant.
Box plots are median and 5% and 95% confidence intervals. GR 800 was a beverage prepared from a
hot-water extract of 3-day old broccoli sprouts that was lyophilized, and then reconstituted in mango
juice and water to deliver 800 µmole glucoraphanin (GR); SF 150 was the hot-water extract cooled to
room temperature, treated with daikon to deliver myrosinase, then lyophilized and later reconstituted
in mango juice and water to deliver 150 µmol of sulforaphane (SF). GR600 + SF 40 were beverages
reconstituted in pineapple juice, lime juice and water from their lyophilized powders to deliver a dose
of 600 µmol of GR and 40 µmol SF. In addition to beverages, a study was conducted with a commercial
dietary supplement formulated as tablets constituted from lyophilized broccoli sprouts and finely
milled broccoli seeds to provide glucoraphanin (75 and 150 µmol) in the presence of myrosinase.
In a cross-over design study we observed recoveries of excreted sulforaphane metabolites
(principally sulforaphane-N-acetylcysteine) to be about 5% when a glucoraphanin-rich beverage was
administered with a ra ge of 1 to 45% but about 70% with a much narrow range of inter-individual
variation when a sulforaphane-rich beverage was used [68]. Thus, bioavailability changes dramatically
as a function of the source material—precursor or bioactive. Some of our subsequent studies used
blends of sulforaphane- and glucoraphanin-rich preparations to improve bioavailability together with
tolerability and to examine dose-response relationships [69,78]. Higher intake was achieved, but
with little impact on inter-in ividual variability. Formulation, which in turn reflects how broccoli
sprout extracts are prepared (e.g., with or without exogenous myrosinase-catalyzed hydrolysis
of glucoraphanin), strongly affects bioavailability. Using a dietary supple ent formulation of
glucoraphanin plus myrosinase (Avmacol®) in tablet form, we observed a median 20% bioavailability
with greatly dampened inter-individual variability. Fahey et al. [67] have observed approximately 35
bioavailability with this supple ent in a different population. Thus, reporting of administered dose of
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glucoraphanin and/or sulforaphane is a poor measure of the bioavailable/bioactive dose of sulforaphane.
As a consequence, we propose that the excreted amount of sulforaphane metabolites (sulforaphane
+ sulforaphane cysteine-glycine + sulforaphane cysteine + sulforaphane N-acetylcysteine) in urine
over 24 h (2–3 half-lives), which is a measure of “internal dose”, provides a more revealing and
likely consistent view of the delivery of sulforaphane to study participants. In turn, use of “internal
dose” metrics will facilitate optimization of the linkage between formulation, dose, and schedule with
determinants of efficacy and, importantly, allow more facile comparisons of results between different
clinical trials.
4.3. Integrating Animal and Clinical Studies
Epidemiological studies have strongly hinted at beneficial associations between crucifer or more
specifically broccoli consumption and mitigation of disease risks. However, it is the animal studies
that have provided a robust foundation for the imperative to conduct clinical trials with broccoli,
broccoli sprouts and derived-preparations or sulforaphane itself. As summarized in the Supplemental
Tables S1–S4, there are a breadth as well as depth of studies describing roles for sulforaphane in the
prevention and treatment of diseases in mouse and rat models.
Yet, animal studies have not delivered all that might be expected of them. It is clear from the
data presented in Figure 5 that the pre-clinical experimentalists have not thought carefully about
the selection of dose (or route) and its relevance to clinical utility. Using oral dosing in mice and rat
studies as examples, over two-thirds of the animal studies have used doses that exceed the highest
(and bordering on intolerable) doses of sulforaphane used in humans, even after accounting for
allometric scaling between rodents and humans. Few studies have included a dose-response; thus, the
greater than 4-log spread of doses used in mice appears to be driven by needs for effect reporting in
publications rather than optimization of translational science. Authors of this review have contributed
to this dose skewing, among many investigators.
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Figure 5. Comparisons of published oral doses of sulforaphane administered to mice or rats and
sulforaphane (tablets or sulforaphane-rich broccoli preparations) or glucoraphanin-rich broccoli
preparations administered to humans. The allometric scaling of the murine doses uses the correction
factor of 0.081 and those for rat doses 0.162 [145]. Human doses were based on an estimate of 70 kg
body weights in each study.
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How were initial doses selected for clinical trials with broccoli-based preparations? Not from any
animal studies, which were already in abundance when the first in human studies were conducted. Not
from pharmacological studies in rodents to define peak plasma levels, half-lives, metabolic fate or tissue
distribution of sulforaphane. Rather, after initial, careful quantitative dose-escalation pharmacokinetic
studies by Talalay and colleagues [26,60,61] with crucifers, clinical trialists quickly sought to push doses
to the extremes of tolerability by attempting to mask the bitter taste of the simple enriched formulations
in order to identify pharmacodynamic action. Only recently have there been attempts to define
minimally effective doses in humans—an outcome made possible by the development of consistently
formulated, stable, bioavailable broccoli-derived preparations. The disconnect between animal and
human studies has been exacerbated because of the public health-based desire (and regulatory-driven
need) to conduct the initial human studies with broccoli-based preparations, that in hindsight varied
greatly in sulforaphane yield and bioavailability, and the expedient use of pure sulforaphane in
most animal studies. Feeding animals lyophilized broccoli or powdered broccoli extracts were likely
disfavored because of the need for high percentages within the diet, which could skew overall nutrient
uptake. Preparations with stabilized sulforaphane now entering clinical use will close the gap in
formulation and could be used to provide more quantitative insights into dose-response [20,102].
Regardless, experimentalists need to now pay close attention to examining efficacy—and underlying
mechanisms—using dose and schedule equivalencies to those that are attainable and tolerable in
humans—and arguably with oral and not intraperitoneal routes of administration. This notion
also extends to in vitro studies, whether in human or animal cell lines, that often report the use of
sulforaphane concentrations in far excess of what is likely achievable in human tissues as peak levels,
never mind the short biological half-life in vivo that quickly attenuates the duration of the exposure.
4.4. Better Efficacy Biomarkers
While there has been substantial progress in the refinement of sourcing and formulation to
optimize the pharmacokinetics of broccoli-based preparations now used in clinical trials, there is
nonetheless limited information on the factors that contribute to the wide inter-individual variation
in pharmacokinetics seen in many clinical trial participants. Host factors (genetic polymorphisms
and epigenetics) as well as host-microbiome interactions likely play important roles in this variability.
Additionally, there is a striking need to develop rigorous biomarkers of pharmacodynamic action.
Better links between purported mechanisms of action delineated in the pre-clinical settings and
functional assessments of clinical efficacy are needed to optimize interventions and to better identify
those healthy or at-risk groups that might best benefit. With more than 50 papers published on clinical
studies with broccoli, glucoraphanin-rich and/or sulforaphane-rich broccoli beverages, powders and
dietary supplements, as well as stabilized formulations of sulforaphane, there is ample optimism for
disease preventing or mitigating applications to continue evolving. The additional listings of more than
50 proposed/ongoing trials in ClinicalTrials.gov also bears witness to such expectations. Short-term
markers of pharmacodynamic actions—likely supported by -omics platforms - are needed to serve as
guideposts for rapid deployment of existing and emerging knowledge for the betterment of health
using broccoli-based strategies.
Supplementary Materials: The following are available online. Table S1: Summary of literature reporting oral
dosing of mice with sulforaphane, Table S2: Summary of literature reporting intraperitoneal dosing of mice with
sulforaphane, Table S3: Summary of literature reporting topical administration of sulforaphane to mice, Table S4:
Summary of literature reporting oral dosing of rats with sulforaphane.
Author Contributions: All authors contributed to the literature survey, compilation of doses, formulations and
outcomes reported, and co-wrote the manuscript.
Funding: This work was supported by the Japan Society for the Promotion of Science [OT 290125], the National
Institutes of Health [R35 CA197222], Washington State Andy Hill CARE Fund, The Lewis B. and Dorothy Cullman
Foundation, Cancer Research UK [C20953/A18644], and BBSRC [BB/L01923X/1].
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Dedication: The lives and careers of the three senior authors on this review have been affected profoundly by 
the friendship and mentoring provided by the late Paul Talalay MD (1923–2019). His visionary precept that 
rigorous, quantitative sciences would serve as the foundation for the discovery, isolation, evaluation, and clinical 
translation of natural products for disease prevention, especially those isolated from vegetables, has guided the 
scientific inquiries discussed in this article. He literally planted the seeds for the continuing evolution of broccoli, 
and specifically sulforaphane, as an effective agent for reducing the burdens of disease in humans as reviewed 
in his “Reflections” writing in the Journal of Biological Chemistry [146] and as reflected in a literature that now 
exceeds 3000 papers. His scientific legacy continues to expand and will be nurtured by many. 
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